22 results
Thumbnail

D3.316 - Impact of chronic urticaria on the quality of life of patients followed up at a university hospital Nis-Serbia

Thumbnail

D3.305 - Pediatric and Adult Responses to Fourth-Fold Antihistamine Doses: Insights into Efficacy and Safety

Thumbnail

D3.306 - Successful treatment of severe atopic dermatitis in teenage patient with hyper-IgE syndrome (STAT3 mutation)

Thumbnail

D3.307 - Experience with Systemic Emergent Therapies for Moderate-to-Severe Atopic Dermatitis: Insights from an Allergy and Clinical Immunology Department

Thumbnail

D3.308 - Frailty in elderly with C1 Inhibitor Hereditary Angioedema: first evidence from a monocentric ITACA cohort

Thumbnail

D3.309 - Challenges in HAE therapy in children

Thumbnail

D3.310 - Hereditary angioedema (HAE) with factor XIIa mutation successfully treated with icatibant as on-demand therapy and lanadelumab for long-term prophylaxis

Thumbnail

D3.311 - Screening for Hereditary Angioedema in Pediatric Patients with Autoinflammatory Diseases and Chronic Abdominal Pain

Thumbnail

D3.312 - Lymphatic supplementation improves atopic dermatitis in dogs

Thumbnail

D3.313 - Chronic Spontaneous Urticaria and its relationship with Allergies to Aerogenic Fungi: dermographism, skin hyperreactivity, and chemical patterns of inflammation

Thumbnail

D3.314 - Sensitization Profile in Patch Tests with the Portuguese Baseline Series in the Algarve

Thumbnail

D3.315 - Airborne allergic contact dermatitis to dry shampoo

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years